Why the study?
Does CYP2C19*17 genotyping have clinical utility?
Does CYP2C19*17 genotyping have clinical utility?
CYP2C19*17 genotyping is unlikely to be clinically useful except for drugs with very narrow therapeutic indices.
Genotyping CYP2C19*17 offers little clinical utility beyond narrow-index drugs; leaves open targeted validation in high-risk pharmacotherapy.
Assignment of CYP2C19*17 homozygotes as extensive metabolizers rather than ultrarapid metabolizers is adequate. CYP2C19*17 genotyping is unlikely to have clinical utility except for drugs with very narrow therapeutic indices.
No takes yet. Share an insight, caveat, or question.
Li‐Wan‐Po et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: